![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
April 15, 2022
Enrollment doubles in past 17 months due to specific efforts — Black participation rises above 20%
April 15, 2022
This study aims to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with pathologic complete response (pCR) after 12 weeks of pre-operative treatment
April 15, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
January 26, 2022
Hopes for a return to normalcy in 2022—plus, recent qualitative research identifies surprising barriers to the long-term control of breast cancer
January 26, 2022
Mary Lou Smith and colleagues at the Research Advocacy Network recently explored how well patients with early-stage breast cancer understand risk of recurrence
December 22, 2021
The co-chairs reflect on key 2021 accomplishments, and share their thanks and best wishes for a happy New Year
October 19, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
July 7, 2021
Could a culturally-sensitive app help improve endocrine therapy medication adherence in Hispanic/Latina patients undergoing breast cancer treatment?
July 7, 2021
Recent ECOG-ACRIN trial updates and results
January 25, 2021
Dr. Sparano discusses the scientific and statistical collaboration behind a new tool, RSClin™, which integrates clinical–pathological and genomic risk information to guide adjuvant chemotherapy in node-negative breast cancer
December 14, 2020
Already among the most influential thought leaders in cardio-oncology, Dr. Ky is the first in this field to receive the Group’s highest research distinction
October 19, 2020
October accrual is on pace to be the highest month on record. Since July 1, TMIST has enrolled more patients than all other National Cancer Institute clinical trials combined. An unheard-of number (nearly 20%) are Black and African American women. Drs. Etta Pisano and Mitch Schnall provide the latest status of the trial and discuss its continuing relevance